Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats

Kohtaro Numaguchi, Kensuke Egashira, Masao Takemoto, Toshiaki Kadokami, Hiroaki Shimokawa, Katsuo Sueishi, Akira Takeshita

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

The aim of the present study was to investigate the effects of long-term blockade of nitric oxide synthesis with the L-arginine analogue Nω-nitro-L-arginine methyl ester (L-NAME) for 8 weeks on coronary vascular and myocardial structural changes. Four groups of Wistar-Kyoto rats were studied: those with no treatment, those treated with L-NAME 1 g/L (3.7 mmol/L in drinking water), those treated with L-NAME 0.1 g/L (0.37 mmol/L in drinking water), and those treated with L-NAME 1.0 g/L and hydralazine 120 mg/L (0.6 mmol/L in drinking water). After 8 weeks, the heart was excised, and the degrees of structural changes in coronary arteries (wall-to-lumen ratio and perivascular fibrosis), myocardial fibrosis, and myocyte size were quantified by an image analyzer. Chronic inhibition of nitric oxide synthesis increased arterial pressure compared with control animals. Chronic inhibition of nitric oxide synthesis caused significant microvascular remodeling (increased wall-to-lumen ratio and perivascular fibrosis). Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis. Coadministration of hydralazine prevented arterial hypertension but did not affect microvascular remodeling and cardiac hypertrophy induced by the chronic inhibition of nitric oxide synthesis. In addition, chronic inhibition of nitric oxide synthesis caused scattered lesions of myocardial fibrosis, which was significantly attenuated by cotreatment with hydralazine. These results suggest that long-term blockade of nitric oxide synthesis caused coronary microvascular remodeling and cardiac hypertrophy in rats in vivo by a mechanism other than arterial hypertension. In contrast, arterial hypertension contributed to the development of myocardial fibrosis induced by long-term blockade of nitric oxide synthesis.

Original languageEnglish
Pages (from-to)957-962
Number of pages6
JournalHypertension
Volume26
Issue number6 I
DOIs
Publication statusPublished - Dec 1995

Fingerprint

Nitric Oxide
Fibrosis
Hydralazine
Arginine
Cardiomegaly
Drinking Water
Hypertension
Inbred WKY Rats
Muscle Cells
Blood Vessels
Coronary Vessels
Arterial Pressure
arginine methyl ester

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Numaguchi, K., Egashira, K., Takemoto, M., Kadokami, T., Shimokawa, H., Sueishi, K., & Takeshita, A. (1995). Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 26(6 I), 957-962. https://doi.org/10.1161/01.HYP.26.6.957

Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. / Numaguchi, Kohtaro; Egashira, Kensuke; Takemoto, Masao; Kadokami, Toshiaki; Shimokawa, Hiroaki; Sueishi, Katsuo; Takeshita, Akira.

In: Hypertension, Vol. 26, No. 6 I, 12.1995, p. 957-962.

Research output: Contribution to journalArticle

Numaguchi, K, Egashira, K, Takemoto, M, Kadokami, T, Shimokawa, H, Sueishi, K & Takeshita, A 1995, 'Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats', Hypertension, vol. 26, no. 6 I, pp. 957-962. https://doi.org/10.1161/01.HYP.26.6.957
Numaguchi, Kohtaro ; Egashira, Kensuke ; Takemoto, Masao ; Kadokami, Toshiaki ; Shimokawa, Hiroaki ; Sueishi, Katsuo ; Takeshita, Akira. / Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. In: Hypertension. 1995 ; Vol. 26, No. 6 I. pp. 957-962.
@article{98d8a97333a040f7a972535d5656bab8,
title = "Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats",
abstract = "The aim of the present study was to investigate the effects of long-term blockade of nitric oxide synthesis with the L-arginine analogue Nω-nitro-L-arginine methyl ester (L-NAME) for 8 weeks on coronary vascular and myocardial structural changes. Four groups of Wistar-Kyoto rats were studied: those with no treatment, those treated with L-NAME 1 g/L (3.7 mmol/L in drinking water), those treated with L-NAME 0.1 g/L (0.37 mmol/L in drinking water), and those treated with L-NAME 1.0 g/L and hydralazine 120 mg/L (0.6 mmol/L in drinking water). After 8 weeks, the heart was excised, and the degrees of structural changes in coronary arteries (wall-to-lumen ratio and perivascular fibrosis), myocardial fibrosis, and myocyte size were quantified by an image analyzer. Chronic inhibition of nitric oxide synthesis increased arterial pressure compared with control animals. Chronic inhibition of nitric oxide synthesis caused significant microvascular remodeling (increased wall-to-lumen ratio and perivascular fibrosis). Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis. Coadministration of hydralazine prevented arterial hypertension but did not affect microvascular remodeling and cardiac hypertrophy induced by the chronic inhibition of nitric oxide synthesis. In addition, chronic inhibition of nitric oxide synthesis caused scattered lesions of myocardial fibrosis, which was significantly attenuated by cotreatment with hydralazine. These results suggest that long-term blockade of nitric oxide synthesis caused coronary microvascular remodeling and cardiac hypertrophy in rats in vivo by a mechanism other than arterial hypertension. In contrast, arterial hypertension contributed to the development of myocardial fibrosis induced by long-term blockade of nitric oxide synthesis.",
author = "Kohtaro Numaguchi and Kensuke Egashira and Masao Takemoto and Toshiaki Kadokami and Hiroaki Shimokawa and Katsuo Sueishi and Akira Takeshita",
year = "1995",
month = "12",
doi = "10.1161/01.HYP.26.6.957",
language = "English",
volume = "26",
pages = "957--962",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6 I",

}

TY - JOUR

T1 - Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats

AU - Numaguchi, Kohtaro

AU - Egashira, Kensuke

AU - Takemoto, Masao

AU - Kadokami, Toshiaki

AU - Shimokawa, Hiroaki

AU - Sueishi, Katsuo

AU - Takeshita, Akira

PY - 1995/12

Y1 - 1995/12

N2 - The aim of the present study was to investigate the effects of long-term blockade of nitric oxide synthesis with the L-arginine analogue Nω-nitro-L-arginine methyl ester (L-NAME) for 8 weeks on coronary vascular and myocardial structural changes. Four groups of Wistar-Kyoto rats were studied: those with no treatment, those treated with L-NAME 1 g/L (3.7 mmol/L in drinking water), those treated with L-NAME 0.1 g/L (0.37 mmol/L in drinking water), and those treated with L-NAME 1.0 g/L and hydralazine 120 mg/L (0.6 mmol/L in drinking water). After 8 weeks, the heart was excised, and the degrees of structural changes in coronary arteries (wall-to-lumen ratio and perivascular fibrosis), myocardial fibrosis, and myocyte size were quantified by an image analyzer. Chronic inhibition of nitric oxide synthesis increased arterial pressure compared with control animals. Chronic inhibition of nitric oxide synthesis caused significant microvascular remodeling (increased wall-to-lumen ratio and perivascular fibrosis). Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis. Coadministration of hydralazine prevented arterial hypertension but did not affect microvascular remodeling and cardiac hypertrophy induced by the chronic inhibition of nitric oxide synthesis. In addition, chronic inhibition of nitric oxide synthesis caused scattered lesions of myocardial fibrosis, which was significantly attenuated by cotreatment with hydralazine. These results suggest that long-term blockade of nitric oxide synthesis caused coronary microvascular remodeling and cardiac hypertrophy in rats in vivo by a mechanism other than arterial hypertension. In contrast, arterial hypertension contributed to the development of myocardial fibrosis induced by long-term blockade of nitric oxide synthesis.

AB - The aim of the present study was to investigate the effects of long-term blockade of nitric oxide synthesis with the L-arginine analogue Nω-nitro-L-arginine methyl ester (L-NAME) for 8 weeks on coronary vascular and myocardial structural changes. Four groups of Wistar-Kyoto rats were studied: those with no treatment, those treated with L-NAME 1 g/L (3.7 mmol/L in drinking water), those treated with L-NAME 0.1 g/L (0.37 mmol/L in drinking water), and those treated with L-NAME 1.0 g/L and hydralazine 120 mg/L (0.6 mmol/L in drinking water). After 8 weeks, the heart was excised, and the degrees of structural changes in coronary arteries (wall-to-lumen ratio and perivascular fibrosis), myocardial fibrosis, and myocyte size were quantified by an image analyzer. Chronic inhibition of nitric oxide synthesis increased arterial pressure compared with control animals. Chronic inhibition of nitric oxide synthesis caused significant microvascular remodeling (increased wall-to-lumen ratio and perivascular fibrosis). Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis. Coadministration of hydralazine prevented arterial hypertension but did not affect microvascular remodeling and cardiac hypertrophy induced by the chronic inhibition of nitric oxide synthesis. In addition, chronic inhibition of nitric oxide synthesis caused scattered lesions of myocardial fibrosis, which was significantly attenuated by cotreatment with hydralazine. These results suggest that long-term blockade of nitric oxide synthesis caused coronary microvascular remodeling and cardiac hypertrophy in rats in vivo by a mechanism other than arterial hypertension. In contrast, arterial hypertension contributed to the development of myocardial fibrosis induced by long-term blockade of nitric oxide synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0028809857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028809857&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.26.6.957

DO - 10.1161/01.HYP.26.6.957

M3 - Article

C2 - 7490155

AN - SCOPUS:0028809857

VL - 26

SP - 957

EP - 962

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6 I

ER -